Omeprazole

Congenital hydronephrosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S4408
R10713		 Pasternak, 2010 Congenital hydronephrosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.93 [0.33;2.62] 4/1,800   -/- - 1,800
ref
S4878
R12804		 Ruigomez (Controls exposed to other treatment, sick), 1999 Renal defects/hydronephrosis 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.36 [0.06;33.59] C
excluded (control group) 		0/139   1/567 1 139
ref
S4877
R12757		 Ruigomez (Controls unexposed NOS), 1999 Renal defects/hydronephrosis 1st trimester retrospective cohort unexposed (general population or NOS) Adjustment: No 2.27 [0.11;47.54] C 0/139   2/1,575 2 139
ref
S4554
R11019		 Källèn (Controls exposed to other treatment, sick), 1998 Hydronephrosis 1st trimester population based cohort retrospective exposed to other treatment, sick Adjustment: No 0.24 [0.01;5.96] C 0/262   1/191 1 262
ref
Total 3 studies 0.90 [0.35;2.30] 3 2,201
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pasternak, 2010Pasternak, 2010 0.93[0.33; 2.62]-1,80082%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ruigomez (Controls unexposed NOS), 1999Ruigomez, 1999 1 2.27[0.11; 47.54]213910%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Källèn (Controls exposed to other treatment, sick), 1998Källèn, 1998 2 0.24[0.01; 5.96]12629%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.90[0.35; 2.30]32,2010.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS; 2: Controls exposed to other treatment, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.90[0.35; 2.30]32,2010%NAPasternak, 2010 Ruigomez (Controls unexposed NOS), 1999 Källèn (Controls exposed to other treatment, sick), 1998 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.02[0.38; 2.72]21,9390%NAPasternak, 2010 Ruigomez (Controls unexposed NOS), 1999 2 exposed to other treatment, sickexposed to other treatment, sick 0.24[0.01; 5.96]1262 -NAKällèn (Controls exposed to other treatment, sick), 1998 1 Tags Adjustment   - No  - No 0.79[0.09; 7.14]34010%NARuigomez (Controls unexposed NOS), 1999 Källèn (Controls exposed to other treatment, sick), 1998 2   - Yes  - Yes 0.93[0.33; 2.62]-1,800 -NAPasternak, 2010 1 All studiesAll studies 0.90[0.35; 2.30]32,2010%NAPasternak, 2010 Ruigomez (Controls unexposed NOS), 1999 Källèn (Controls exposed to other treatment, sick), 1998 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 4878

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.02[0.38; 2.72]21,9390%NAPasternak, 2010 Ruigomez (Controls unexposed NOS), 1999 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.57[0.06; 5.53]24010%NARuigomez (Controls exposed to other treatment, sick), 1999 Källèn (Controls exposed to other treatment, sick), 1998 20.510.01.0